Mode
Text Size
Log in / Sign up
Phase 2 Completed N=72 Randomized Quadruple-blind Treatment

Study of Thymosin Beta 4 in Patients With Venous Stasis Ulcers

Venous Stasis Ulcers
Source: ClinicalTrials.gov NCT00832091 ↗
Enrolled (actual)
72
Serious AEs
5.6%
Results posted
Mar 2010
Primary outcomePrimary: Safety and Tolerability of Thymosin Beta 4 (Tβ4) Applied to Patients With Venous Stasis (VS) Ulcers for up to 84 Days — 24; 104 SAEs and AEs

Summary

The purpose of this study is to evaluate the safety, tolerability and effectiveness of Thymosin Beta 4 administered topically in patients with Venous Stasis ulcers

Outcome Measures

OutcomeResultp-value
PRIMARY
Safety and Tolerability of Thymosin Beta 4 (Tβ4) Applied to Patients With Venous Stasis (VS) Ulcers for up to 84 Days
24; 104
SECONDARY
Wound Healing (Wound Closure Without Drainage) by Applying Tβ4 Gel Once Daily for up to 84 Days to Patients With Venous Stasis (VS) Ulcers
4; 12

Eligibility Criteria

Inclusion Criteria

  • Informed Consent Form signed by the patient
  • Male or female, between 18 and 79 years of age
  • At least one venous leg ulceration stable for at least 6 weeks before enrollment
  • Surface area between 3 and 30 cm2

Exclusion Criteria

  • Have clinical evidence of active infection on the index ulcer
  • Use of any experimental drug, or participation in any clinical study, within the 60 days before enrollment
  • Use of systemic or topical steroidal therapy, immunotherapy, or cytotoxic chemotherapy within the 60 days before enrollment
  • History of adverse reaction to any ingredients of the study medication
  • Clinically significant neurological, cardiovascular, respiratory, hepatic, renal, metabolic and dermatologic disease other than venous ulcers
  • Current or former malignancy
  • Arterial disorder resulting in ulcerated ulcers
  • Diabetes mellitus
  • Pregnant or lactating (breastfeeding) women. A serum pregnancy test will be performed at screening for female patients of childbearing potential
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00832091). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search